A single nucleotide polymorphism inADIPOQpredicts biochemical recurrence after radical prostatectomy in localized prostate cancer

Abstract

Adiponectin has been implicated in prostate cancer (PCa) aggressiveness. However, the role of genetic variations in the adiponectin (ADIPOQ) gene in PCa progression remains unknown. To determine whether genetic variants in ADIPOQ are associated with the risk of biochemical recurrence (BCR) after radical prostatectomy (RP). We evaluated three common ADIPOQ polymorphisms in 728 men with clinically localized PCa who underwent RP. Multivariable Cox proportional hazards models and Kaplan–Meier analysis were used to assess their prognostic significance on BCR. The plasma adiponectin concentrations were measured by enzyme-linked immunosorbent assay. ADIPOQ rs182052 variant allele was associated with both increased risk of BCR [HR: 2.44; 95% confidence interval (CI): 1.57–3.79, P = 6×10−5] and decreased adiponectin level (β = −0.048, P = 0.004). Stratified analyses demonstrated that the association was more pronounced in men with higher visceral adipose tissue. Our data support that the ADIPOQ rs182052 SNP may be a predictive biomarker for BCR after RP by a possible mechanism of altering the adiponectin level. If validated, genetic predictors of outcome may help individualizing treatment for PCa.

Genetic variants of the CYP1B1 gene as predictors of biochemical recurrence after radical prostatectomy in localized prostate cancer patients

“…We retrospectively analyzed 738 men who had undergone RP from 2 independent cohorts in China as described previously. [ 19 ] The 1st cohort was composed of 312 patients from the Affiliated Hospital of Qingdao University and Fudan University Shanghai Cancer Center, and the 2nd was composed of 426 patients from Fudan University Shanghai Cancer Center. The median follow-up times were 36.3 and 37.7 months.…”

Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population

“…In this regard, genetic markers among cancer patients appears have been increasingly investigated. To date, several promising polymorphisms have not been used to screen for prostate cancer or incorporate into nomograms to predict patient survivals, however, may provide potential useful information to optimize the diagnosis, therapy and follow-up of patients with prostate cancer 22 23 24 .…”

A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length

“…The study subjects were mostly from previously published case-control study 7 . Briefly, 1115 eligible patients recruited into this study were newly diagnosed and histopathologically confirmed primary prostate adenocarcinoma from Fudan University Shanghai Cancer Center (FUSCC) between January 2005 and January 2012, of whom 1015 (92%) agreed to participate in this study.…”